JUPITER, Fla., June 17, 2013 /PRNewswire/ — BioRestorative Therapies, Inc. (BRTX:$1.00,00$0.00,000.00%) (“BRT” or the “Company”) – Financial personality and Founder of NBT Equities Research, Tobin Smith, recently interviewed BioRestorative Therapies, Inc. (BRTX:$1.00,00$0.00,000.00%) (the “Company”) CEO, Mark Weinreb, on the firm’s hybrid business model and what the firm is currently doing that will help change the biotechnology landscape. BioRestorative is a life sciences company focused on developing stem cell based cellular therapies for various personal medical applications.
NBT Equities Research interviews CEOs and industry leaders in the emerging growth sector and emerging growth sector advocacy groups to discuss trends and developments along with company updates.
Topics discussed by Mr. Weinreb include an update on the Company’s ThermoStem™ Program designed to develop treatments using brown fat stem cells for metabolic disorders and obesity focused on potentially preventing the onset of Type 2 diabetes. Specifically, Mr. Weinreb shares the encouraging observation that it has made strides in preclinical development based on animal data.
In addition, Mr. Weinreb discusses the brtxDISC™ Program that encompasses a novel way of cell culturing and includes a medical device designed for the re-transplantation of an individual’s own stem cells into the disc area for repair. This program is nearing readiness for clinical trials.
The interview can be heard on the NBT Equities Research website at the following link:

http://direct.nbtequitiesresearch.com/video/nbt-biorestorative-1

About BioRestorative Therapies, Inc. (BRTX:$1.00,00$0.00,000.00%)
BioRestorative Therapies, Inc. (BRTX:$1.00,00$0.00,000.00%) (“BRT”), www.biorestorative.com, develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives:
brtxDISC™ Program (Disc Implanted Stem Cells), a non-surgical treatment for bulging and herniated discs that addresses the gap between non-invasive and invasive back procedures. This research is still in the non-clinical, investigational stage.
ThermoStem®Program, a treatment for metabolic disorders (diabetes, heart disease, etc.) and obesity using brown fat stem cells. Initial non-clinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels in the body.
brtx-C Cosmetic Program, based on the development of a human cellular extract that, per initial in vitro studies, when applied to human skin cells, appears to cause an increase in the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.
The Company also offers plant stem cell-based facial creams and beauty products under the Stem Pearls® brand at www.stempearls.com.
This press release and the interview contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company’s Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
Investor Contact:
Adam Holdsworth

ProActive Capital
646.862.4607
adamh@proactivecapital.com
Media Contact:
Sandra Lee
ProActive Capital
646.862.4608
slee@proactivecapital.com

SOURCE BioRestorative Therapies, Inc. (BRTX:$1.00,00$0.00,000.00%)

Get more news on:SYMBOLS: BRTXNEWS TYPE: SECTORS: Health Care, Life Sciences Tools and Services, Pharmaceuticals, Health Care Providers and Services

NEW YORK, June 17, 2013 (GLOBE NEWSWIRE) — NeoStem, Inc. (NBS:$0.54,00$0.00,000.00%) (“NeoStem” or the “Company”), a leader in the emerging cellular therapy market, today announced the geographic expansion of intellectual property protection around its lead product candidate, AMR-001, with the notice of a patent allowance in Canada. This patent is in the family titled “Compositions and Methods of Vascular Injury Repair” and protects a chemotactic stem cell product enriched for CD34+ cells that treats injury from acute myocardial infarction (“AMI”).
“This incremental patent will bring AMR-001′s total worldwide patent coverage to ten patents,” said Dr. Andrew L. Pecora, Chief Medical Officer of NeoStem (NBS:$0.54,00$0.00,000.00%) . “If our trial results warrant regulatory approval, after launch in the U.S., Canadian expansion of AMR-001 sales would be a logical step and creates the potential to access a nearby market where heart attack and cardiovascular disease are significant threats to public health.”
According to reports, cardiovascular disease is a significant problem in Canada. The population of Canada is approximately 35.5 million with an estimated 70,000 heart attacks occurring each year. Heart disease accounts for over 20% of deaths in Canada.
NeoStem’s (NBS:$0.54,00$0.00,000.00%) AMR-001 is a cell therapy in development for the treatment of cardiovascular disease. The Company is on track to complete enrollment this year in the Phase 2 PreSERVE AMR-001 double-blinded clinical trial to investigate AMR-001′s safety and efficacy in preserving heart function after a heart attack in a particular type of post-AMI patient. NeoStem (NBS:$0.54,00$0.00,000.00%) expects to have the first data readout available six to eight months after the last patient is enrolled. If approved by the U.S. Food and Drug Administration (“FDA”) and/or other worldwide regulatory agencies, AMR-001 would address a significant unmet medical need in the treatment of AMI and position the Company to capture a meaningful share of the worldwide AMI market.
“Canada is yet another significant possible market for AMR-001. With a strong patent portfolio already under our belts, we look forward to further expansion of our intellectual property in the coming years,” said Dr. Robin L. Smith, Chairman and CEO of NeoStem (NBS:$0.54,00$0.00,000.00%) .
About NeoStem, Inc. (NBS:$0.54,00$0.00,000.00%)
NeoStem, Inc. (NBS:$0.54,00$0.00,000.00%) (“NeoStem” or the “Company”) is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization (“CDMO”) providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.
For more information, please visit: www.neostem.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, including with respect to the Company’s research and development and clinical evaluation efforts for cellular therapies, including with respect to AMR-001, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company’s ability to successfully grow its contract development and manufacturing business. The Company’s actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company’s periodic filings with the SEC. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
CONTACT: NeoStem (NBS:$0.54,00$0.00,000.00%)
Dr. Robin L. Smith
Chairman and CEO
Phone: +1-212-584-4174
Email: rsmith@neostem.com
Image: NeoStem Inc. (NBS:$0.54,00$0.00,000.00%) Logo

Get more news on:SYMBOLS: NBSNEWS TYPE: SECTORS: Health Care, Health Care Providers and Services

Dr. Thomson was recognized for his study of human embryonic stem cells and the new possibilities they create for developing cell-based therapies, modelling disease and testing toxicity His work has been cited in TIME Magazine’s “Top 10 Discoveries of the Year” on three separate occasions, and in 2007, he was named one of TIME’s “100 Most Influential People in the World.”

Dr. Thomson was the first person to isolate human embryonic stem cells and discovered how to reprogram adult cells without eggs or embryos. It is because of Dr. Thomson’s ground-breaking discoveries that an entire new generation of stem-cell scientists is closing in on new ways to not only treat diseases such as cancer, diabetes and heart disease, but to cure them.

“When we first considered supporting regenerative medicine research a decade ago, we were inspired by what we read about Dr. Thomson’s work,” said Cheryl McEwen, who along with her husband Robert McEwen, established the McEwen Centre For Regenerative Medicine in 2003.

Dr. Thomson is the Director of Regenerative Biology at the Morgridge Institute for Research in Madison Wisconsin and holds professorships at both the University of Wisconsin School of Medicine and Public Health and the University of California, Santa Barbara. He has published over 150 scientific, peer-reviewed papers and has been an inventor on 30 issued patents.

He was presented with his award at the International Society for Stem Cell Research (ISSCR) 11th Annual Meeting in Boston, Massachusetts, USA, during the Presidential Symposium on Wednesday, June 12, 2013. The ISSCR is an independent, nonprofit organization formed in 2002 to foster the exchange of information on stem cell research.

The McEwen Award for Innovation, supported by the McEwen Centre for Regenerative Medicine, recognizes original thinking and ground-breaking research pertaining to stem cells or regenerative medicine that opens new avenues of exploration towards the understanding or treatment of human disease or affliction. The winner is honoured with the $100,000 award at the ISSCR Annual Meeting.

Toronto General & Western Hospital Foundation
190 Elizabeth Street, 5th Floor
Toronto, Ontario M5G 2C4
Canada

You are subscribed to this newsletter as icell@investorstemcell.com. Please click here to modify your message preferences or to unsubscribe from any future mailings. We will respect all unsubscribe requests.

——————————————————————————–

SubmitEdge SubmitEdge Launches Social Media Optimization (SMO) Services 6:03 am 48 k
iStockphoto iStockphoto Hot Shots – 06.13.2013 5:45 am 19 k
AWeber Communications, Inc. Receipt for Invoice: 18570173 Login: investorstemcel 2:27 am 19 k
Facebook Your weekly Page update Wed, 10:28 pm 13 k
StemCell Media URGENT: License Expired (aMember Pro) Wed, 10:00 pm 1 k
John C. Kirkland Violation of Terms of Use Wed, 4:34 pm 3 k
Wildfire by Google [Report] The Road to Social ROI – Building a strategy for success Wed, 10:56 am 17 k
McEwen Centre for Regenerative Medicine Dr. James Thomson receives 2013 McEwen Award For Innovation Wed, 8:49 am 6 k
Auto Parts Warehouse In case you missed this week’s offering: Get up to $15 OFF Wed, 8:16 am 16 k
Nicolas Hertz Your Press Release in Spain and Latin America Wed, 8:05 am 9 k
PR Awards Submit your Top Places to Work in PR entry by this Friday! Wed, 6:09 am 14 k
BioTime ALERT: New BioTime SEC Filing Wed, 6:06 am 10 k
BioTime BioTime Appoints Henry L. Nordhoff to Board of Directors Wed, 6:03 am 27 k
SEO Expert Link Building & SEO Services Wed, 3:54 am 14 k
StemCell Media URGENT: License Expired (aMember Pro) Tue, 10:00 pm 2 k
Twitter InvestorStemCell.com, you have a new follower on Twitter! Tue, 9:01 pm 23 k
EMIL SLAVIK via PayPal Notification of payment received Tue, 7:46 pm 17 k
PR News Writing Boot Camp August 5 in San Francisco Tue, 3:07 pm 13 k
New England Patriots Tim Tebow Joins the Patriots Tue, 12:19 pm 12 k
PR Press PR News’ Media Training Guidebook Tue, 11:40 am 12 k
NFL.com Fantasy Activate Your 2013 NFL Fantasy League Now! Tue, 10:04 am 10 k
Twitter Stem Cell Foundation, Biotec Research, and 6 others have Tweets for you Tue, 9:22 am 94 k
Salary.com Newsletter How Much Money are Dads Worth in 2013? Tue, 9:08 am 53 k
Amy Jefferies PR News Announces Next Practices Annual Conference Tue, 6:15 am 12 k
StemCell Media URGENT: License Expired (aMember Pro) Mon, 9:00 pm 2 k
Constant Contact New England – Corissa St. Laurent Save the date! Small Business Week is almost here Mon, 11:38 am 51 k
Wildfire by Google Learn how to run a social sweepstakes and you might win a prize Mon, 10:50 am 17 k
PR News Engage New Audiences with Visual Content – June 13 Webinar Mon, 9:47 am 14 k
Auto Parts Warehouse Shop early for Dad’s Day | Here’s $10 and $15 Savings Mon, 8:16 am 46 k
Auto Parts Warehouse ☑ Shop early for Dad’s Day – Here’s $10 and $15 Savings! Mon, 8:09 am 46 k
Genetics Policy Institute 360: the 60 second stem cell/regenmed news bulletin from univerCELLmarket and GPI w/e June 9, 2013 Mon, 8:03 am 67 k
Twitter Reset your Twitter password Mon, 7:14 am 6 k
Facebook John Prouty updated his status: “Thanks Akron Public for teaching my son…” Mon, 6:45 am 15 k
NESTOR ATIENZA Fw: ‘ACTC’ News — ACT’s Dr. Robert Lanza to Deliver the Keynote Addr… Mon, 6:09 am 17 k
Facebook Jeremy invited you to Hair Trigger Johnson – Live @ The Cliffside on Facebook Mon, 5:19 am 15 k
StemCell Media URGENT: License Expired (aMember Pro) Sun, 9:00 pm 1 k
Twitter InvestorStemCell.com, you have a new follower on Twitter! Sun, 7:53 pm 23 k
Amazon.com Your Amazon.com order of “Pampers Swaddlers Diapers…” has shipped! Sun, 3:09 pm 20 k
auto-confirm@amazon.com Your Order with Amazon.com Sun, 8:35 am 17 k
StemCell Media URGENT: License Expired (aMember Pro) Sat, 9:00 pm 2 k
Preview
Move to FolderMove to FolderMore ActionsMore Actions

For a complete listing of our news releases, please click here

ALAMEDA, Calif.–(BUSINESS WIRE)–Jun. 12, 2013– BioTime, Inc. (NYSE MKT: BTX) today announced that Henry L. Nordhoff, former CEO and Chairman of Gen-Probe Inc., has been appointed to its Board of Directors.

“We are pleased to welcome an accomplished healthcare executive of Hank’s caliber to BioTime’s board,” said Alfred D. Kingsley, Chairman of the Board of BioTime. “Hank’s 43 years of experience in the pharmaceutical business, including most recently his leadership role in managing impressive growth at Gen-Probe over a 15-year period should prove valuable as BioTime continues to pursue multiple growth opportunities.”

“BioTime is a leading company in the emerging field of Regenerative Medicine,” said Mr. Nordhoff. “I am pleased to be joining BioTime at this important juncture, as the company moves towards translating a magnificent array of technologies into products, and then introducing those products into the marketplace to alleviate suffering and cure diseases.”

Mr. Nordhoff is the former CEO and Chairman of Gen-Probe, Inc., a leading molecular diagnostics company which was acquired in 2012 in an all-cash transaction that valued the company at $3.72 billion. Under Mr. Nordhoff’s leadership, Gen-Probe introduced numerous innovative diagnostic products to test for a host of infectious disease-causing viruses and bacteria, screening products to help identify compatible transplant matches, and instruments and assays to screen donated blood for diseases. Prior to joining Gen-Probe in 1994, Mr. Nordhoff served as President and CEO of TargeTech, Inc., a gene therapy and antisense company that merged into the Immune Response Corporation; as President and CEO of American Biogenetic Sciences, Inc., a monoclonal antibody company that went public during his tenure; as Vice President of Acquisitions and Business Development at Sterling Drug Inc.; and in a number of senior positions at Pfizer Inc. in Brussels, Seoul, Tokyo and New York. Mr. Nordhoff holds a Master’s in Business Administration from Columbia University and a Bachelor of Arts in International Relations and Political Economy from Johns Hopkins University.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is enhanced through subsidiaries focused on specific fields of application. BioTime develops and markets research products in the fields of stem cells and regenerative medicine, including a wide array of proprietary PureStemTM cell lines, HyStem® hydrogels, culture media, and differentiation kits. BioTime is developing ReneviaTM (formerly known as HyStem®-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. BioTime’s therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime’s majority owned subsidiary Cell Cure Neurosciences Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. BioTime’s subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product PanC-DxTM currently being developed for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is developing applications of BioTime’s proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime’s subsidiary LifeMap Sciences, Inc. markets GeneCards®, the leading human gene database, as part of an integrated database suite that also includes the LifeMap DiscoveryTM database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. LifeMap Sciences also markets BioTime research products and PanDaTox, an innovative, recently developed, searchable database that can aid in the discovery of new antibiotics and biotechnologically beneficial products. Asterias Biotherapeutics, Inc. is a new subsidiary being used to acquire the stem cell assets of Geron Corporation, including patents and other intellectual property, biological materials, reagents and equipment for the development of new therapeutic products for regenerative medicine. BioTime’s lead product, Hextend®, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements. Additional information about BioTime can be found on the web at www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime’s Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com

Source: BioTime, Inc.

BioTime, Inc.
Robert Peabody, 510-521-3390, ext 302
Sr. VP & CFO
rpeabody@biotimemail.com
or
Judith Segall, 510-521-3390, ext 301
jsegall@biotimemail.com

——————————————————————————–
If you are unable to click on the link above, please copy and paste the URL below into a web browser

http://investor.biotimeinc.com/phoenix.zhtml?c=83805&p=IROL-news&nyo=0

Thomson Reuters Inc. 22 Thomson Place Boston, MA 02210
Click Here to unsubscribe from this JoinMail list.

——————————————————————————–

SubmitEdge SubmitEdge Launches Social Media Optimization (SMO) Services 6:03 am 48 k
iStockphoto iStockphoto Hot Shots – 06.13.2013 5:45 am 19 k
AWeber Communications, Inc. Receipt for Invoice: 18570173 Login: investorstemcel 2:27 am 19 k
Facebook Your weekly Page update Wed, 10:28 pm 13 k
StemCell Media URGENT: License Expired (aMember Pro) Wed, 10:00 pm 1 k
John C. Kirkland Violation of Terms of Use Wed, 4:34 pm 3 k
Wildfire by Google [Report] The Road to Social ROI – Building a strategy for success Wed, 10:56 am 17 k
McEwen Centre for Regenerative Medicine Dr. James Thomson receives 2013 McEwen Award For Innovation Wed, 8:49 am 6 k
Auto Parts Warehouse In case you missed this week’s offering: Get up to $15 OFF Wed, 8:16 am 16 k
Nicolas Hertz Your Press Release in Spain and Latin America Wed, 8:05 am 9 k
PR Awards Submit your Top Places to Work in PR entry by this Friday! Wed, 6:09 am 14 k
BioTime ALERT: New BioTime SEC Filing Wed, 6:06 am 10 k
BioTime BioTime Appoints Henry L. Nordhoff to Board of Directors Wed, 6:03 am 27 k
SEO Expert Link Building & SEO Services Wed, 3:54 am 14 k
StemCell Media URGENT: License Expired (aMember Pro) Tue, 10:00 pm 2 k
Twitter InvestorStemCell.com, you have a new follower on Twitter! Tue, 9:01 pm 23 k
EMIL SLAVIK via PayPal Notification of payment received Tue, 7:46 pm 17 k
PR News Writing Boot Camp August 5 in San Francisco Tue, 3:07 pm 13 k
New England Patriots Tim Tebow Joins the Patriots Tue, 12:19 pm 12 k
PR Press PR News’ Media Training Guidebook Tue, 11:40 am 12 k
NFL.com Fantasy Activate Your 2013 NFL Fantasy League Now! Tue, 10:04 am 10 k
Twitter Stem Cell Foundation, Biotec Research, and 6 others have Tweets for you Tue, 9:22 am 94 k
Salary.com Newsletter How Much Money are Dads Worth in 2013? Tue, 9:08 am 53 k
Amy Jefferies PR News Announces Next Practices Annual Conference Tue, 6:15 am 12 k
StemCell Media URGENT: License Expired (aMember Pro) Mon, 9:00 pm 2 k
Constant Contact New England – Corissa St. Laurent Save the date! Small Business Week is almost here Mon, 11:38 am 51 k
Wildfire by Google Learn how to run a social sweepstakes and you might win a prize Mon, 10:50 am 17 k
PR News Engage New Audiences with Visual Content – June 13 Webinar Mon, 9:47 am 14 k
Auto Parts Warehouse Shop early for Dad’s Day | Here’s $10 and $15 Savings Mon, 8:16 am 46 k
Auto Parts Warehouse ☑ Shop early for Dad’s Day – Here’s $10 and $15 Savings! Mon, 8:09 am 46 k
Genetics Policy Institute 360: the 60 second stem cell/regenmed news bulletin from univerCELLmarket and GPI w/e June 9, 2013 Mon, 8:03 am 67 k
Twitter Reset your Twitter password Mon, 7:14 am 6 k
Facebook John Prouty updated his status: “Thanks Akron Public for teaching my son…” Mon, 6:45 am 15 k
NESTOR ATIENZA Fw: ‘ACTC’ News — ACT’s Dr. Robert Lanza to Deliver the Keynote Addr… Mon, 6:09 am 17 k
Facebook Jeremy invited you to Hair Trigger Johnson – Live @ The Cliffside on Facebook Mon, 5:19 am 15 k
StemCell Media URGENT: License Expired (aMember Pro) Sun, 9:00 pm 1 k
Twitter InvestorStemCell.com, you have a new follower on Twitter! Sun, 7:53 pm 23 k
Amazon.com Your Amazon.com order of “Pampers Swaddlers Diapers…” has shipped! Sun, 3:09 pm 20 k
auto-confirm@amazon.com Your Order with Amazon.com Sun, 8:35 am 17 k
StemCell Media URGENT: License Expired (aMember Pro) Sat, 9:00 pm 2 k
Preview
Move to FolderMove to FolderMore ActionsMore Actions

(MORE TO FOLLOW) Dow Jones Newswires (212-416-2800)
06-13-130801ET
Copyright (c) 2013 Dow Jones & Company, Inc.

SUNRISE, FL–(Marketwired – Jun 12, 2013) – Bioheart, Inc. (OTCQB: BHRT) announced today that they have successfully enrolled and treated all patients in the phase I ANGEL Trial. The trial, which is fully funded by Bioheart, is being conducted in Mexico at the Hospital Angeles with the Regenerative Medicine Institute (RMI). This phase I study will provide necessary safety and preliminary efficacy of adipose-derived stem cells in patients with congestive heart failure. Endpoints include safety, exercise capacity, quality of life, and ejection fraction at 3 months, 6 months and 12 months.

Kristin Comella, Bioheart’s Chief Science Officer, said, “We were so excited to see brisk enrollment in the study. Once we collect preliminary safety and efficacy, we will expand the study into a Phase II trial.”

About Bioheart, Inc.
Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart’s goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient’s quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “would,” “estimate,” or “continue” or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2012, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013.

Contact Information

Bioheart, Inc.
13794 NW 4th Street
Suite 212
Sunrise, FL 33325
Telephone 954-835-1500
Email: rmadaris@bioheartinc.com

Will Present Final ALS Phase I Results Including New Cervical Cohort Data
ROCKVILLE, Md., June 10, 2013 /CNW/ – Neuralstem, Inc. (CUR:$1.53,00$0.05,003.38%) today reported that Eva Feldman, MD, PhD, will address the Canadian Neurological Sciences Federation Annual Congress, in Montreal, Canada, on Thursday, June 13th at 8:30 a.m. ET as a grand plenary speaker (http://congress.cnsfederation.org/). Dr. Feldman will present final data from Neuralstem’s (CUR:$1.53,00$0.05,003.38%) Phase I trial testing NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). Adding to her presentation at a medical conference last month in Romania, Dr. Feldman will discuss new data from the patient cohorts treated in the cervical region.
(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )
Dr. Feldman is the principal investigator for the trial, which was recently approved by the FDA to commence to Phase II. She is also Director of the A. Alfred Taubman Medical Research Institute, Director of Research of the ALS Clinic at the University of Michigan Health System and the President of the American Neurological Association. Dr. Feldman is an unpaid consultant to Neuralstem (CUR:$1.53,00$0.05,003.38%) .
About Neuralstem (CUR:$1.53,00$0.05,003.38%)
Neuralstem’s (CUR:$1.53,00$0.05,003.38%) patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem (CUR:$1.53,00$0.05,003.38%) completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease, in February 2013, and has received FDA approval to begin Phase II. Neuralstem (CUR:$1.53,00$0.05,003.38%) has been awarded orphan status designation by the FDA for its ALS cell therapy.
In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company received approval to commence a Phase I safety trial in chronic spinal cord injury in January 2013.
Neuralstem (CUR:$1.53,00$0.05,003.38%) also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem (CUR:$1.53,00$0.05,003.38%) has discovered and patented compounds that may stimulate the brain’s capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company is in the last cohort of a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include traumatic brain injury (TBI), Alzheimer’s disease, and post-traumatic stress disorder (PTSD).
For more information, please visit www.neuralstem.com or connect with us on Twitter, Facebook and LinkedIn
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem’s (CUR:$1.53,00$0.05,003.38%) technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s (CUR:$1.53,00$0.05,003.38%) periodic reports, including the annual report on Form 10-K for the year ended December 31, 2012 and the Form 10-Q for the period ended March 30, 2013.

Get more news on:SYMBOLS: CURNEWS TYPE: SECTORS: Health Care, Pharmaceuticals, Health Care Providers and Services, Materials, Metals and Mining

NEWARK, Calif., June 10, 2013 (GLOBE NEWSWIRE) — StemCells, Inc. (STEM:$1.8301,$-0.0099,-0.54%) today announced key hires to strengthen its product development capabilities and announced the creation of a new corporate function responsible for establishing scientific and strategic alliances and for building on the Company’s existing stem cell technology platform.
Eliseo Salinas, M.D., has joined the Company as Executive Vice President and Head of Research and Development, and will be responsible for the Company’s research, product development and clinical translation activities. Dr. Salinas will report to Martin McGlynn, President and CEO of the Company.
Ann Tsukamoto, Ph.D., who has most recently served as the Company’s Executive Vice President of Research and Development, will assume the new role of Executive Vice President, Scientific and Strategic Alliances, responsible for developing the Company’s alliances with research institutions, corporations, government agencies and disease foundations. Dr. Tsukamoto will continue to report to Mr. McGlynn.
The Company also announced that Nicki Vasquez, Ph.D., has joined the Company as Vice President of Program and Portfolio Management, and Allyson Gage, Ph.D., has joined as Senior Director of Clinical Development.
“The Company’s clinical trials have so far been single-arm open-label studies, involving a small number of patients and conducted at one or two clinical sites,” said Mr. McGlynn. “These trials, however, have generated a growing body of encouraging human data, providing us with strong rationale to begin preparing for controlled, Phase II, proof of concept studies in multiple disease indications, involving larger patient numbers and multiple trial sites internationally. The addition of Eliseo, Nicki and Allyson is an integral part of our strategy to ensure we have the expertise and bandwidth to succeed in this next step of the Company’s path to market approval.
“Meanwhile, I am delighted to have Ann assume the role of EVP for Scientific and Strategic Alliances. This will be Ann’s fifth leadership role here at StemCells (STEM:$1.8301,$-0.0099,-0.54%) , and there is no one better qualified to take charge of building on our existing relationships with state and federal agencies, such as the National Institutes of Health and the California Institute for Regenerative Medicine, and with other important stakeholders, such as the International Society for Stem Cell Research and the various disease foundations. In addition, Ann will play an important role in helping us stay abreast of the rapidly evolving scientific and technological developments that could have far-reaching implications for the Company’s long-term success.”
Dr. Tsukamoto has been a groundbreaking researcher in the field of stem cell biology for more than twenty years. She joined the Company in February 1998 as Senior Director, Scientific Operations, and has held several leadership roles at the Company, most recently as Executive Vice President of Research and Development since September 2008. Dr. Tsukamoto was a co-discoverer of the human hematopoietic stem cell while at SyStemix, Inc., and played a leading role at StemCells (STEM:$1.8301,$-0.0099,-0.54%) in the isolation of the human neural stem cell as well as populations of human liver and pancreatic cells with stem cell-like properties. Dr. Tsukamoto received her doctorate from the University of California, Los Angeles, and did postdoctoral research at the University of California, San Francisco.
In his new role, Dr. Salinas will focus on accelerating completion of the Company’s ongoing trials in spinal cord injury and age-related macular degeneration, as well as advancing the Company’s plans for a Phase II study in Pelizaeus-Merzbacher disease. Dr. Salinas has more than 20 years of experience and expertise developing therapeutic products for central nervous system (CNS) disorders in many key jurisdictions worldwide, including the United States, Canada, the European Union, and Japan. Under his leadership, 15 programs obtained regulatory approval in the United States and other major international markets. Prior to joining StemCells (STEM:$1.8301,$-0.0099,-0.54%) , Dr. Salinas was Executive Vice President, Head of Development, and Chief Medical Officer of Elan Pharmaceuticals. Before joining Elan, Dr. Salinas was Senior Vice President, Research and Development and Chief Medical Officer of Adolor Coproration; Executive Vice President, Speciality Pharma, Research and Development and Chief Scientific Officer of Shire plc; and held roles of increasing responsibility in research and development at Wyeth-Ayerst Research, including head of worldwide CNS product development. Dr. Salinas earned his medical degree from the University of Buenos Aires, Argentina, performed a residency in psychiatry in Paris at the Clinique des Maladies Mentales et de l’Encéphale, and obtained a master’s degree in pharmacology from the Université Pierre et Marie Curie, Académie de Paris, France.
Both Drs. Vasquez and Gage are experts in product development in the biotech industry. Dr. Vasquez was most recently Vice President, Global Development Program & Portfolio Management at Elan Pharmaceuticals. She earned her doctorate in immunology and bachelor’s degree in microbiology from the University of California, San Diego. Dr. Gage has held senior roles in clinical development at Elan and Forest Laboratories, Inc. She earned her doctorate and master’s degree in neuroscience from Albert Einstein College of Medicine.
In connection with their hire, the Company has granted Drs. Salinas, Vasquez and Gage an aggregate total of 496,965 restricted stock units (RSUs). Each grant was made pursuant to the Company’s 2012 Commencement Incentive Plan and in accordance with Nasdaq Listing Rule 5635(c)(4) concerning inducement grants to new employees. Each RSU gives the holder the right to receive upon vesting, without cash payment, a share of StemCells (STEM:$1.8301,$-0.0099,-0.54%) common stock. With the exception of 11,765 RSUs, which vested three days after grant, all of these granted RSUs have four-year vesting schedules so that they vest in four equal parts on each of their first four service anniversaries, starting in 2014 and ending in 2017.
About StemCells, Inc. (STEM:$1.8301,$-0.0099,-0.54%)
StemCells, Inc. (STEM:$1.8301,$-0.0099,-0.54%) is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company’s lead therapeutic product candidate, HuCNS-SC® cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company is also conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and has reported positive interim data for the first three patients. The Company has also initiated a Phase I/II clinical trial in dry age-related macular degeneration (AMD), and is pursuing preclinical studies in Alzheimer’s disease. StemCells (STEM:$1.8301,$-0.0099,-0.54%) also markets stem cell research products, including media and reagents, under the SC Proven® brand. Further information about StemCells (STEM:$1.8301,$-0.0099,-0.54%) is available at http://www.stemcellsinc.com.
Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the timing and prospect of initiating a Phase II clinical trial in PMD and concluding the Company’s on-going trials in spinal cord injury and AMD; the Company’s ability to successfully execute its product development activities; and the future business operations of the Company. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management’s current views and are based on certain assumptions that may or may not ultimately prove valid. The Company’s actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including the fact that additional trials will be required to demonstrate the safety and efficacy of the Company’s HuCNS-SC cells for the treatment of any disease or disorder; uncertainty as to whether the FDA, Health Canada or other applicable regulatory agencies will permit the Company to continue clinical testing in spinal cord injury, AMD or in future clinical trials of proposed therapies for other diseases or conditions; uncertainties regarding the Company’s ability to obtain the increased capital resources needed to continue its current and planned research and development operations; uncertainty as to whether HuCNS-SC cells and any products that may be generated in the future in the Company’s cell-based programs will prove safe and clinically effective and not cause tumors or other adverse side effects; uncertainties regarding the Company’s ability to commercialize a therapeutic product and its ability to successfully compete with other products on the market; and other factors that are described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012, and in its subsequent reports on Form 10-Q and Form 8-K.
CONTACT: Rodney YoungStemCells, Inc. (STEM:$1.8301,$-0.0099,-0.54%)
Chief Financial Officer
(510) 456-4128

Ian StoneRusso Partners
(619) 308-6541
Image: company logo

Get more news on:SYMBOLS: STEMNEWS TYPE: SECTORS: Health Care, Pharmaceuticals

HAIFA, Israel, June 10, 2013 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI:$2.93,00$-0.10,00-3.30%) , a leading developer of placenta-based cell therapies, announced today that Pluristem’s CEO and its Project Innovation Research Manager will be delivering two different presentations during Israel’s largest biotechnology conference, the 12th Annual IATI-BioMed ConferenceJune 10th through 12th, 2013 in Tel Aviv.
Zami Aberman, Pluristem’s Chairman and CEO, has been invited to speak at a satellite symposium on June 11th entitled “Haifa -Life sciences: innovation and excellence at its best”. Mr. Aberman will present details of the company, as Pluristem exemplifies the type of success story in the life sciences created at Haifa’sMATAM Advanced Technology Park. Accompanying Mr. Aberman to the podium will be Mr. Yona Yahav, Mayor of the City of Haifa and Professor Dan Shechtman, Nobel Laureate in Chemistry, Technion – Israel Institute of Technology, who will be the keynote speaker.
Additionally, on June 11th, Eytan Abraham PhD, Project Innovation Research Manager at Pluristem, will give a lecture entitled “Systemic Therapeutic Effect of Placental Expanded Cells (PLX) Following Local Administration in Hind Limb Ischemia Model,” and will present data illustrating that the local intramuscular (IM) administration of PLX-PAD cells can produce a systemic effect in this animal model.
About Pluristem Therapeutics (PSTI:$2.93,00$-0.10,00-3.30%)
Pluristem Therapeutics Inc. (PSTI:$2.93,00$-0.10,00-3.30%) is a leading developer of placenta-based cell therapies. The Company’s patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company’s proprietary 3D micro-environmental technology and are an “off-the-shelf” product that requires no tissue matching prior to administration.
Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.
The Pluristem Therapeutics Inc. (PSTI:$2.93,00$-0.10,00-3.30%) logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6882
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when we discuss that local intramuscular (IM) administration of PLX-PAD cells can produce a systemic effect in this animal model we are using forward-looking statements. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem’s reports filed from time to time with the Securities and Exchange Commission.
CONTACT: Pluristem Therapeutics Inc. (PSTI:$2.93,00$-0.10,00-3.30%) :

William Prather R.Ph., M.D. Sr. VP Corporate Development
1-303-883-4954
William.PratherMD@pluristem.com

Daya Lettvin
Investor & Media Relations Director
+972-54-674-5580
daya@pluristem.com
Image: Pluristem Therapeutics Inc. (PSTI:$2.93,00$-0.10,00-3.30%) Logo

Get more news on:SYMBOLS: PSTINEWS TYPE: SECTORS: Health Care, Life Sciences Tools and Services, Pharmaceuticals

MARLBOROUGH, Mass.–(BUSINESS WIRE)– Advanced Cell Technology, Inc. (ACTC:$0.08,00$-0.0005,-0.62%) , a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.D., will be delivering the Keynote Address at the BWH Regenerative Medicine Center Inaugural Symposium, being held at Brigham & Women’s Hospital in Boston on June 11. The Symposium will showcase an exciting array of research in regenerative medicine; highlighting the work of both nationally and internationally recognized investigators and that of the rising stars working in this domain. Dr. Lanza’s address, titled “Pluripotent Stem Cells – Moving From Bench to Bedside,” will take place at 4 p.m. EDT in the Bornstein Family Amphitheater & Cabot Atrium.
The newly formed Regenerative Medicine Center at Brigham & Women’s Hospital is a marriage of stem cell biology with state-of-the-art engineering and nanotechnology, integrating the talents of engineers, physicists and mathematicians with those of biologists and clinicians. BWH investigators are nationally and internationally recognized for their contributions to advances in stem cell, regenerative medicine and tissue engineering research as recipients of prestigious awards, including elected members of numerous scientific and medical organizations. In addition to Dr. Lanza’s Keynote Address, the Symposium will include sessions about “Pluripotent Stem Cells & Basic Developmental Biology,” “Adult Stem Cells & Disease” and “Novel Technologies in Regenerative Medicine.”
About Advanced Cell Technology, Inc. (ACTC:$0.08,00$-0.0005,-0.62%)
Advanced Cell Technology, Inc. (ACTC:$0.08,00$-0.0005,-0.62%) , is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2012. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.
Source: Advanced Cell Technology, Inc. (ACTC:$0.08,00$-0.0005,-0.62%)

Get more news on:SYMBOLS: ACTCNEWS TYPE: SECTORS: Health Care, Pharmaceuticals